OrthogenRx, Inc. is a medical device company focused on the development and commercialization of treatments for musculoskeletal conditions including osteoarthritis (OA). Our first commercial product is GenVisc® 850 (sodium hyaluronate)* indicated for the treatment of osteoarthritic knee pain.*GenVisc 850 prescribing information
OrthogenRx senior management has over 50 years’ experience in the biopharma industry and 30 years’ experience with the sales, marketing and reimbursement of products in the targeted class of medical devices. Board members and leading advisors include those with expertise in FDA law and regulations, reimbursement, emerging company management and investment, sales & marketing and mergers & acquisitions, as well as includes nationally recognized law firms in intellectual property law and general corporate counsel, all contributing to a world class management and advisory team.